Research programme: anxiety and neurological disorder therapeutics - AstraZeneca

Drug Profile

Research programme: anxiety and neurological disorder therapeutics - AstraZeneca

Alternative Names: 5-HT1A receptor antagonists - AstraZeneca; AZ 12320927

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Karolinska Institute; University of Texas Southwestern Medical Center
  • Class
  • Mechanism of Action Opioid delta receptor agonists; Serotonin 1A receptor antagonists; Serotonin 1B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Alzheimer's disease; Anxiety disorders; Major depressive disorder

Most Recent Events

  • 21 Oct 2009 Preclinical trials in Alzheimer's disease in Sweden (unspecified route)
  • 15 Oct 2008 AstraZeneca and Columbia University enter research collaboration
  • 03 Sep 2008 Interim pharmacodynamics data from a preclinical trial in Anxiety disorders presented at the 21st Annual Congress of the European College of Neuropsychopharmacology (ECNP-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top